Evidence map›Paper›PMID 42490752›Full record

Trial reportJournal of radiation research2026

Image-guided moderately hypofractionated proton beam therapy for localized prostate cancer: 5-year outcomes of a phase II trial.

Takashi Iizumi, Hitoshi Ishikawa, Yuta Sekino, Motohiro Murakami, Keiichi Tanaka, Daichi Takizawa, Hirokazu Makishima, Yutaro Mori, Satoshi Kamizawa, Masashi Mizumoto and 4 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Journal of radiation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takashi IizumiDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.ORCID 0000-0001-6632-4356
Hitoshi IshikawaDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.ORCID 0000-0002-0046-9787
Yuta SekinoDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
Motohiro MurakamiDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
Keiichi TanakaDepartment of Radiation Oncology, Tsuchiura Kyodo General Hospital, 4-1-1, Otsuno, Tsuchiura, Ibaraki 300-0028, Japan.
Daichi TakizawaDepartment of Radiation Oncology, Hitachi General Hospital, Hitachi Ltd., 2-1-1 Jonancho, Hitachi, Ibaraki 317-0077, Japan.
Hirokazu MakishimaQST Hospital, National Institutes for Quantum Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba, Chiba 263-8555, Japan.
Yutaro MoriDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
Satoshi KamizawaDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
Masashi MizumotoDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.ORCID 0000-0001-7837-1301
Toshiyuki OkumuraDepartment of Radiation Oncology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, 6528 Koibuchi, Kasama,  Ibaraki 309-1793, Japan.
Hiroyoshi SuzukiDepartment of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba 263-8555, Japan.
Hiroyuki NishiyamaDepartment of Urology, Faculty of Medicine and Graduate School of Comprehensive Human Science, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.
Hideyuki SakuraiDepartment of Radiation Oncology and Proton Medical Research Center, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8576, Japan.ORCID 0000-0002-0576-8639

Funding

JSPS 24 K108-99
6 · The paper itself

Abstract

The purpose of the present study is to confirm the efficacy and feasibility of moderately hypofractionated proton beam therapy (PBT) at a total dose of 63 Gy relative biological effectiveness (RBE) in 21 fractions for prostate cancer. This phase II clinical trial (PPS-002: UMIN 000017679) enrolled 125 men with histologically confirmed prostate cancer (cT1c-3aN0M0). The primary endpoint was grade ≥2 late gastrointestinal (GI) toxicities. Secondary endpoints included biochemical recurrence rates, clinical recurrence rates, overall survival (OS) and acute toxicities and late genitourinary (GU) toxicities. With a median follow-up period of 71.0 months (IQR: 60-84), the 5-year cumulative incidences of late grade 2 or higher GI and GU adverse events (AEs) were 3.3% and 8.1%, respectively. Biochemical recurrences were observed in three patients; no clinical recurrences occurred. The 5-year biochemical recurrence-free, clinical recurrence-free and OS rates were 97.6% (95% CI: 94.9-100.0), 100% and 97.5% (95% CI: 94.8-100.0), respectively. The long-term follow-up results of moderately hypofractionated PBT of 63 Gy (RBE) in 21 fractions confirmed low incidences of late AEs, successfully meeting the primary endpoint. Furthermore, the low incidence of tumor recurrence supports the overall safety and feasibility of this fractionation schedule.

Indexed as

Prostatic NeoplasmsProton TherapyRadiation Dose HypofractionationRadiotherapy, Image-GuidedAgedAged, 80 and overDose Fractionation, RadiationHumansMaleMiddle AgedNeoplasm Recurrence, LocalTreatment Outcomehypofractionationlate toxicityprospective studyprostate cancerproton beam therapy

Identifiers

PMID42490752

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.